RCMI Coordinating Center (RCMI CC) Header Logo

COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center.

Vawter NL, Godino JG, Lewis SV, Northrup AW, Samaniego JC, Poblete JY, Guereca JA, Sharp SP, Matthews E, Crespo NC, Lucatero PG, Vidaurrazaga MM, Ramers CB. COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center. BMC Infect Dis. 2023 Feb 22; 23(1):105.

View in: PubMed

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support